Pat Lawman is chief executive officer of Morphogenesis Incorporated and a member of the company’s board of directors. She cofounded Morphogenesis in 1995, bringing a scientific background in immunology and molecular biology to this cell and gene therapy company.
Dr. Lawman manages corporate direction and strategy at Morphogenesis and the company’s wholly-owned subsidiary, Veterinary Oncology Services Incorporated, facilitating company activity in internal R&D initiatives, alliances, and product development. She is also responsible for directing quality management and regulatory compliance. Since forming Morphogenesis, Dr. Lawman has worked to develop and share Morphogenesis’ vision and mission to partners, shareholders, and investors.
In 2012, Dr. Lawman was recognized by Tampa Bay Business Journal as Technology Business Woman of the Year and has been featured in Florida Trend Magazine and the Tampa Bay Business Journal. She has held adjunct faculty positions at the University of Central Florida and the University of South Florida and has served on numerous committees at local, state and federal levels. Dr. Lawman holds over 25 patents and as many publications and was coeditor of Springer Verlag’s Cancer Vaccines. Dr. Lawman received her graduate education in molecular biology and immunology from the College of Medicine at the University of Florida.
Previously, Dr. Lawman served as chief operations officer of Morphogenesis, where her focus was on innovation, execution, and improved efficiency to streamline operations. Prior to founding Morphogenesis, she was Division Director of Cancer Molecular Biology at the Walt Disney Memorial Cancer Institute where she initiated and coordinated molecular biology, gene targeting and universal stem cell programs.